Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cengild Medical BhdXKLS:0243 +2.63%61 EV-to-EBITDA is 9.84 as of Aug. 07, 2026, which is 2% above its 10-year median of 9.62. GuruFocus rates XKLS:0243 with a GF Score™ of 61/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Cengild Medical Bhd ranks better than 56.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cengild Medical Bhd's enterprise value is RM193.56 Mil.
Cengild Medical Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was RM19.68 Mil. Therefore, Cengild Medical Bhd's EV-to-EBITDA for today is 9.84.
The historical rank and industry rank for Cengild Medical Bhd's EV-to-EBITDA or its related term are showing as below:
XKLS:0243'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.17 Med: 9.62 Max: 32.72
Current: 9.84
During the past 8 years, the highest EV-to-EBITDA of Cengild Medical Bhd was 32.72. The lowest was 5.17. And the median was 9.62.
XKLS:0243's EV-to-EBITDA is ranked better than 56.86% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs XKLS:0243: 9.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cengild Medical Bhd (XKLS:0243) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cengild Medical Bhd's PE Ratio (TTM) for today is calculated as:
Cengild Medical Bhd's share price for today is RM0.195.
Cengild Medical Bhd's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cengild Medical Bhd's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0243 vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Cengild Medical Bhd's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cengild Medical Bhd EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cengild Medical Bhd's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cengild Medical Bhd's EV-to-EBITDA falls into.
Cengild Medical Bhd's current Enterprise Value is RM193.56 Mil.
Cengild Medical Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM19.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cengild Medical Bhd (XKLS:0243) has a EV-to-EBITDA of 9.84 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cengild Medical Bhd. This is near median its historical median of 9.62. Over the past decade, Cengild Medical Bhd's EV-to-EBITDA has ranged from 5.17 to 32.72. According to the industry distribution chart, Cengild Medical Bhd ranks #220 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 43.1%.
Is Cengild Medical Bhd's EV-to-EBITDA too high?
Cengild Medical Bhd's current EV-to-EBITDA of 9.84 is near median its 10-year median of 9.62. Over the past 10 years, this metric has ranged from a low of 5.17 to a high of 32.72. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Cengild Medical Bhd's value of 9.84 is 9.9% below this industry median. Based on the distribution chart, Cengild Medical Bhd ranks #220 out of 510 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cengild Medical Bhd has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cengild Medical Bhd ranks #220 out of 510 companies for EV-to-EBITDA. This puts Cengild Medical Bhd in the upper half of its industry. The industry median EV-to-EBITDA is 10.92. Cengild Medical Bhd's value of 9.84 is 9.9% below this benchmark. Historically, Cengild Medical Bhd's own EV-to-EBITDA has ranged from 5.17 to 32.72 over the past decade. While the company's 10-year median is 9.62 vs. the industry median of 10.92, Cengild Medical Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cengild Medical Bhd's current EV-to-EBITDA of 9.84 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cengild Medical Bhd. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current EV-to-EBITDA is 9.84, which is near median its own 10-year median of 9.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 32.8% below its estimated fair value. The current EV-to-EBITDA is 9.84, which is near median its 10-year median of 9.62 and 9.9% below the Healthcare Providers & Services industry median of 10.92. Cengild Medical Bhd's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current EV-to-EBITDA is 9.84 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?
Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued.
The current stock price of RM0.20 is trading 32.8% below its estimated GF Value™ of RM0.29.
GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0243:
EV-to-EBITDA: 9.84 (near median its 10-year median of 9.62)
GF Value™: RM0.29 vs. price of RM0.20 (32.8% below fair value)
Industry Position: 9.9% below the Healthcare Providers & Services median (#220 of 510)
No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
61GF Score
Get the complete analysis for XKLS:0243
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0243 has been successfully added to your 
